secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2023-12-14T23:59:59+00:00
Accession:  0001193125-23-295039
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.05, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Reneo's mavodelpar fails Phase 3 STRIDE study; cuts workforce 70%
-----------------------------------------------------------------

- Pivotal STRIDE trial of mavodelpar in primary mitochondrial myopathies missed primary endpoint (12MWT at week 24) and key secondary.
- Company suspends all mavodelpar development including STRIDE AHEAD; workforce reduced ~70%.
- Estimated Q4 2023 charges of ~$2.5M for severance and termination-related costs.
- Company has >$100M in cash, cash equivalents, and short-term investments to fund operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000119312523295039/0001193125-23-295039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000119312523295039/d553352d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-295039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer